{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:19:06Z","timestamp":1793254746742,"version":"4.5.0"},"reference-count":216,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med"],"abstract":"<jats:p>The use of cancer immunotherapies is not novel but has been used over the decades in the clinic. Only recently have we found the true potential of stimulating an anti-tumor response after the breakthrough of checkpoint inhibitors. Cancer immunotherapies have become the first line treatment for many malignancies at various stages. Nevertheless, the clinical results in terms of overall survival and progression free survival were not as anticipated. Majority of cancer patients do not respond to immunotherapies and the reasons differ. Hence, further improvements for cancer immunotherapies are crucially needed. In the review, we will discuss various forms of cancer immunotherapies that are being tested or already in the clinic. Moreover, we also highlight future directions to improve such therapies.<\/jats:p>","DOI":"10.3389\/fmmed.2023.1140977","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T01:47:46Z","timestamp":1676598466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Cancer immunotherapies: A hope for the uncurable?"],"prefix":"10.3389","volume":"3","author":[{"given":"Firas","family":"Hamdan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0190084","DOI":"10.1371\/JOURNAL.PONE.0190084","article-title":"High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features","volume":"12","author":"Achkar","year":"2017","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3389\/fmicb.2016.01503","article-title":"Components of adenovirus genome packaging","volume":"7","author":"Ahi","year":"2016","journal-title":"Front. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3389\/FMICB.2016.01503","article-title":"Components of adenovirus genome packaging","volume":"7","author":"Ahi","year":"2016","journal-title":"Front. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/mi.2009.112","article-title":"PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions","volume":"3","author":"Akbari","year":"2010","journal-title":"Mucosal Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/ITT.S61590","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria","year":"2015","journal-title":"Immunotargets Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/SJ.BJC.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4161\/mabs.3.4.16092","article-title":"A next generation of therapeutic antibodies?","volume":"3","author":"Bakema","year":"2011","journal-title":"MAbs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"128.15","DOI":"10.4049\/jimmunol.196.supp.128.15","article-title":"PD-1 inhibits the TCR signaling cascade by sequestering SHP-2 phosphatase, preventing its translocation to lipid rafts and facilitating Csk-mediated inhibitory phosphorylation of Lck","volume":"196","author":"Bardhan","year":"2016","journal-title":"J. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: The next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4161\/MABS.3.5.17334","article-title":"Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies","volume":"3","author":"Beck","year":"2011","journal-title":"MAbs"},{"key":"B11","volume-title":"Ueber das Zustandekommen der Diphtherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren","author":"Behring","year":"2013"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/SCIENCE.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1073\/PNAS.74.8.3171","article-title":"Spliced segments at the 5\u2019 terminus of adenovirus 2 late mRNA","volume":"74","author":"Berget","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2008.18.0463","article-title":"Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan","volume":"27","author":"Bibeau","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/NRC3246","article-title":"The determinants of tumour immunogenicity","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/S12967-015-0680-0","article-title":"Analysis of in vitro ADCC and clinical response to trastuzumab: Possible relevance of Fc\u03b3RIIIA\/Fc\u03b3RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines","volume":"13","author":"Boero","year":"2015","journal-title":"J. Transl. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/emmm.201201929","article-title":"IgAEGFR antibodies mediate tumour killing in vivo","volume":"5","author":"Boross","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/IJC.29536","article-title":"Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans","volume":"137","author":"Bramante","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/2326-6066.CIR-15-0099-T","article-title":"Simultaneous targeting of Fc\u03b3Rs and Fc\u03b1RI enhances tumor cell killing","volume":"3","author":"Brandsma","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"54722","DOI":"10.18632\/oncotarget.18039","article-title":"PD-L1\/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/BLOOD.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/1873-3468.13695","article-title":"Viral and cellular interactions during adenovirus DNA replication","volume":"593","author":"Charman","year":"2019","journal-title":"FEBS Lett."},{"key":"B25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1368-7646(03)00040-2","article-title":"Strategies to target HER2\/neu overexpression for cancer therapy","volume":"6","author":"Chen","year":"2003","journal-title":"Drug Resist Updat"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.3390\/V7112905","article-title":"Oncolytic replication of e1b-deleted adenoviruses","volume":"7","author":"Cheng","year":"2015","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","article-title":"An amazing sequence arrangement at the 5\u2019 ends of adenovirus 2 messenger RNA","volume":"12","author":"Chow","year":"1977","journal-title":"Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/BLOOD-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/BLOOD-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/SCIENCE.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/BJC.1986.39","article-title":"Increased EGF receptors on human squamous carcinoma cell lines","volume":"53","author":"Cowley","year":"1986","journal-title":"Br. J. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/J.1600-065X.2009.00766.X","article-title":"The significance of OX40 and OX40L to T cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"key":"B34","volume-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 Axis","author":"Dahan","year":"2015"},{"key":"B35","first-page":"1","article-title":"High-dose interleukin-2 (hd IL-2) for advanced melanoma: A single center experience from the","volume-title":"J. Immunother. Cancer","author":"Davar","year":"2017"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-09-4109","article-title":"In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling","volume":"70","author":"De Haij","year":"2010","journal-title":"Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-662-05597-7_7","article-title":"Adenovirus DNA replication: Protein priming, jumping back and the role of the DNA binding protein DBP","volume":"272","author":"De Jong","year":"2003","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/NRI2803","article-title":"Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules","volume":"10","author":"De Saint Basile","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1182\/blood-2002-03-0687","article-title":"Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing","volume":"100","author":"Dechant","year":"2002","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0022-2836(81)90208-4","article-title":"Structure of the linkage between adenovirus DNA and the 55,000 molecular weight terminal protein","volume":"145","author":"Desiderio","year":"1981","journal-title":"J. Mol. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/JIMMUNOL.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"10988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"1919","author":"Dias","year":"2011","journal-title":"Gene Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/SCIENCE.1248943\/SUPPL_FILE\/DIEBOLDER.SM.PDF","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/307521A0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/ANNUREV.IMMUNOL.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0923-2494(97)84219-8","article-title":"Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis","volume":"148","author":"Eischen","year":"1997","journal-title":"Res. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.4049\/jimmunol.1600811","article-title":"Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells","volume":"197","author":"Engelberts","year":"2016","journal-title":"J. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.4049\/JIMMUNOL.1800087","article-title":"Comment on \u201ctype I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells","volume":"200","author":"Evers","year":"2018","journal-title":"J. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1795505","DOI":"10.1080\/19420862.2020.1795505","article-title":"Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies","volume":"12","author":"Evers","year":"2020","journal-title":"MAbs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/159499A0","article-title":"Plasma cellular reaction and its relation to the formation of antibodies in vitro","volume":"159","author":"Fagraeus","year":"1947","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/NRI.2017.140","article-title":"The dawn of vaccines for cancer prevention","volume":"18","author":"Finn","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B55","volume-title":"Public attitudes to science 2019","author":"for Business","year":"2020"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.15252\/EMMM.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T\u2010cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/NAR\/GKR1076","article-title":"Chromatin structure of adenovirus DNA throughout infection","volume":"40","author":"Giberson","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1182\/BLOOD-2012-03-415364","article-title":"Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells","volume":"119","author":"Gill","year":"2012","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1084\/JEM.148.4.1093","article-title":"Long-term culture of human antigen-specific cytotoxic T-cell lines","volume":"148","author":"Gillis","year":"1978","journal-title":"J. Exp. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/268154A0","article-title":"Long term culture of tumour-specific cytotoxic T cells","volume":"268","author":"Gillis","year":"1977","journal-title":"Nature"},{"key":"B62","first-page":"1","article-title":"The molecular basis of adenovirus pathogenesis","volume":"3","author":"Ginsberg","year":"1994","journal-title":"Infect. Agents Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: A CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/BLOOD.V97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice","volume":"97","author":"Grote","year":"2001","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0309-1651(84)90045-6","article-title":"Cellular localisation of human epidermal growth factor receptor","volume":"8","author":"Gusterson","year":"1984","journal-title":"Cell. Biol. Int. Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e003000","DOI":"10.1136\/JITC-2021-003000","article-title":"Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids","volume":"9","author":"Hamdan","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/J.CELL.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B68","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1128\/JVI.71.3.1842-1849.1997","article-title":"Construction of adenovirus vectors through Cre-lox recombination","volume":"71","author":"Hardy","year":"1997","journal-title":"J. Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1001\/JAMA.299.22.2667","article-title":"The role of chemotherapy at the end of life: \u201cWhen is enough, enough?\u201d","volume":"299","author":"Harrington","year":"2008","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"B72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/J.TIPS.2015.11.004","article-title":"Adoptive T cell therapies: A comparison of T cell receptors and chimeric antigen receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/BLOOD-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1073\/PNAS.95.5.2509","article-title":"A simplified system for generating recombinant adenoviruses","volume":"95","author":"He","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e134680","DOI":"10.1172\/JCI134680","article-title":"Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity","volume":"131","author":"Heemskerk","year":"2021","journal-title":"J. Clin. Investig."},{"key":"B76","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1172\/JCI9762","article-title":"Replication-selective adenoviruses as oncolytic agents","volume":"105","author":"Heise","year":"2000","journal-title":"J. Clin. Investigation"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.18632\/ONCOTARGET.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"B80","volume-title":"National vital statistics reports volume 68, number 6, June 24, 2019, deaths: Leading causes for 2017","author":"Heron","year":"2019"},{"key":"B81","doi-asserted-by":"publisher","first-page":"20140239","DOI":"10.1098\/RSTB.2014.0239","article-title":"The analysis of clonal expansions in normal and autoimmune B cell repertoires","volume":"370","author":"Hershberg","year":"2015","journal-title":"Philosophical Trans. R. Soc. B Biol. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1128\/CMR.5.3.262","article-title":"Adenoviruses in the immunocompromised host","volume":"5","author":"Hierholzer","year":"1992","journal-title":"Clin. Microbiol. Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"a013003","DOI":"10.1101\/CSHPERSPECT.A013003","article-title":"Adenovirus DNA replication","volume":"5","author":"Hoeben","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"14","author":"Hollingsworth","year":"20194201","journal-title":"npj Vaccines"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2010-02-271981","article-title":"Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2","volume":"116","author":"Huber","year":"2010","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1158\/0008-5472.CAN-10-4222","article-title":"Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy","volume":"71","author":"Hubert","year":"2011","journal-title":"Cancer Res."},{"key":"B90","first-page":"5778","article-title":"Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies","volume":"59","author":"Huls","year":"1999","journal-title":"Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/SCIENCE.AAR6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e1652538","DOI":"10.1080\/2162402X.2019.1652538","article-title":"The impact of CTLA-4 blockade and interferon-\u03b1 on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients","volume":"8","author":"Khunger","year":"2019","journal-title":"Oncoimmunology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/J.1365-2567.2007.02587.X","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495A0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1073\/PNAS.75.7.3405","article-title":"Study of antibodies against human melanoma produced by somatic cell hybrids","volume":"75","author":"Koprowski","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J. Exp. Med."},{"key":"B98","volume-title":"Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma","author":"Kurbacher","year":"2005"},{"key":"B99","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/JAMAONCOL.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J. Immunother."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/S00262-020-02729-Y","article-title":"Combination therapies utilizing neoepitope-targeted vaccines","volume":"70","author":"Lee","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/J.1365-2141.2001.02995.X","article-title":"Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells","volume":"114","author":"Lehmann","year":"2001","journal-title":"Br. J. Haematol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/J.OMTM.2020.01.001","article-title":"Oncolytic viruses and the immune system: The dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B105","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2015.09.005","article-title":"IgA as therapeutic antibody","volume":"68","author":"Leusen","year":"2015","journal-title":"Mol. Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/J.CCR.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell."},{"key":"B107","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s1074-7613(00)80480-x","article-title":"Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"key":"B108","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/SJ.GT.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"25139","DOI":"10.1074\/jbc.M112.353060","article-title":"Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages","volume":"287","author":"Lohse","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.4049\/jimmunol.1003082","article-title":"Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing","volume":"186","author":"Lohse","year":"2011","journal-title":"J. Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"456796","DOI":"10.1038\/sj.onc.1208836","article-title":"Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K","volume":"24","author":"Lomonosova","year":"2005","journal-title":"Oncogene"},{"key":"B112","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/BJC.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"Br. J. Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma - the first phase I\/IIa trial","volume":"16","author":"Malmstr\u00f6m","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"14429","DOI":"10.1128\/JVI.79.22.14429-14436.2005","article-title":"CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7","volume":"79","author":"Marttila","year":"2005","journal-title":"J. Virol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.4049\/jimmunol.164.10.5319","article-title":"Structural analysis of CTLA-4 function in vivo","volume":"164","author":"Masteller","year":"2000","journal-title":"J. Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3389\/FONC.2019.01146","article-title":"Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front. Oncol."},{"key":"B117","first-page":"177","article-title":"Next-generation sequencing for cancer diagnostics: A practical perspective","volume":"32","author":"Meldrum","year":"2011","journal-title":"Clin. Biochem. Rev."},{"key":"B118","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/J.MOLIMM.2015.01.028","article-title":"Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics","volume":"67","author":"Melis","year":"2015","journal-title":"Mol. Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0168-1702(93)90090-A","article-title":"Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter","volume":"28","author":"Mittal","year":"1993","journal-title":"Virus Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/SCIENCE.147.3660.873","article-title":"CONTACT-INDUCED cytotoxicity by lymphoid cells containing foreign isoantigens","volume":"147","author":"M\u00f6ller","year":"1965","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/CAS.13548","article-title":"Anti\u2010human SIRP\u03b1 antibody is a new tool for cancer immunotherapy","volume":"109","author":"Murata","year":"2018","journal-title":"Cancer Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B123","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/NRD3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B125","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/NBT0409-331","article-title":"Development trends for therapeutic antibody fragments","volume":"27","author":"Nelson","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-3527(08)60419-4","article-title":"Processing of adenovirus nuclear RNA to mRNA","volume":"26","author":"Nevins","year":"1981","journal-title":"Adv. Virus Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/0092-8674(78)90071-5","article-title":"Steps in the processing of Ad2 mRNA: poly(A)+ nuclear sequences are conserved and poly(A) addition precedes splicing","volume":"15","author":"Nevins","year":"1978","journal-title":"Cell."},{"key":"B128","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/J.IT.2015.04.005","article-title":"Fc\u03b3R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities","volume":"36","author":"Nimmerjahn","year":"2015","journal-title":"Trends Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-1-59745-570-1_9","article-title":"Analyzing antibody-Fc-receptor interactions","volume":"415","author":"Nimmerjahn","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/NRI2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/1811419A0","article-title":"Antibody production by single cells","volume":"181","author":"Nossal","year":"1958","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-662-05597-7_6","article-title":"Regulation of adenovirus packaging","volume":"272","author":"Ostapchuk","year":"2003","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"B134","doi-asserted-by":"publisher","first-page":"212","DOI":"10.6004\/jadpro.2015.6.3.3","article-title":"The toxicity and benefit of various dosing strategies for interleukin-2 in metastatic melanoma and renal cell carcinoma","volume":"6","author":"Pachella","year":"2015","journal-title":"J. Adv. Pract. Oncol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/CVI.00475-09","article-title":"Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids","volume":"17","author":"Pakkanen","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4049\/jimmunol.141.3.849","article-title":"Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones","volume":"141","author":"Paliard","year":"1988","journal-title":"J. Immunol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3324\/haematol.2011.061408","article-title":"Anti-CD20 IgA can protect mice against lymphoma development: Evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells","volume":"97","author":"Pascal","year":"2012","journal-title":"Haematologica"},{"key":"B139","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/IJO_00000125\/HTML","article-title":"Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR\/HER-2 heterodimerization and activation","volume":"34","author":"Patel","year":"2009","journal-title":"Int. J. Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1182\/BLOOD-2008-03-144600","article-title":"Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells","volume":"112","author":"Peipp","year":"2008","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med. J."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e000510","DOI":"10.1136\/ESMOOPEN-2019-000510","article-title":"New emerging targets in cancer immunotherapy: The role of cluster of differentiation 40 (CD40\/TNFR5)","volume":"4","author":"Piechutta","year":"2019","journal-title":"ESMO Open"},{"key":"B144","doi-asserted-by":"publisher","first-page":"e29467","DOI":"10.1371\/JOURNAL.PONE.0029467","article-title":"The E1B19K oncoprotein complexes with beclin 1 to regulate autophagy in adenovirus-infected cells","volume":"6","author":"Piya","year":"2011","journal-title":"PLoS One"},{"key":"B145","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00003495-200666040-00005","article-title":"Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer","volume":"66","author":"Plosker","year":"2006","journal-title":"Drugs"},{"key":"B146","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/11206840-000000000-00000","article-title":"Sipuleucel-T: In metastatic castration-resistant prostate cancer","volume":"71","author":"Plosker","year":"2011","journal-title":"Drugs"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1172\/JCI1348","article-title":"Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice","volume":"101","author":"Proietti","year":"1998","journal-title":"J. Clin. Investig."},{"key":"B150","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/S41598-017-00747-Y","article-title":"The 5\u2019UTR in human adenoviruses: Leader diversity in late gene expression","volume":"7","author":"Ramke","year":"2017","journal-title":"Sci. Rep."},{"key":"B151","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/S40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors \u2013 An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0092-8674(77)90045-9","article-title":"Identification of a protein linked to the ends of adenovirus DNA","volume":"11","author":"Rekosh","year":"1977","journal-title":"Cell."},{"key":"B153","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/NRI3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323A0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"B157","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/J.EJCA.2012.01.007","article-title":"Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer","volume":"48","author":"Rodr\u00edguez","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"B160","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/SCIENCE.AAA4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B161","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/NRC2355","article-title":"Adoptive cell transfer: A clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/JNCI\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"B163","doi-asserted-by":"publisher","first-page":"7823585107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B164","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/J.1365-2567.2000.00121.X","article-title":"CD28, CTLA-4 and their ligands: Who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"B165","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/S12967-017-1182-Z","article-title":"Adenovirus-mediated CD40L gene transfer increases Teffector\/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients","volume":"15","author":"Schiza","year":"2017","journal-title":"J. Transl. Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1126\/science.1131078","article-title":"Reversal of the TCR stop signal by CTLA-4","volume":"313","author":"Schneider","year":"2006","journal-title":"Science"},{"key":"B167","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/244444A0","article-title":"Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types","volume":"244","author":"Schwaber","year":"1973","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1700187","DOI":"10.1002\/MABI.201700187","article-title":"Solid tumor immunotherapy with T cell engager-armed oncolytic viruses","volume":"18","author":"Scott","year":"2018","journal-title":"Macromol. Biosci."},{"key":"B169","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2165\/00063030-200519060-00002","article-title":"Strategies of tumor immune evasion","volume":"19","author":"Seliger","year":"2005","journal-title":"BioDrugs"},{"key":"B170","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/333565A0","article-title":"The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria","volume":"333","author":"Selvaraj","year":"1988","journal-title":"Nature"},{"key":"B171","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1128\/JVI.02131-09\/ASSET\/B26DCBCF-2ACD-4DCA-8A8C-A418B02E0AE0\/ASSETS\/GRAPHIC\/ZJV9990930500007.JPEG","article-title":"E1A interacts with two opposing transcriptional pathways to induce quiescent cells into S phase","volume":"84","author":"Sha","year":"2010","journal-title":"J. Virol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/J.CELL.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell."},{"key":"B173","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/CAAC.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B174","doi-asserted-by":"publisher","first-page":"15043","DOI":"10.1038\/MTM.2015.43","article-title":"Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells","volume":"2","author":"Sioud","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B175","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/SCIENCE.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann. Oncol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"13499","DOI":"10.1016\/S0021-9258(18)33475-6","article-title":"Adenovirus terminal protein precursor. Partial amino acid sequence and the site of covalent linkage to virus DNA","volume":"257","author":"Smart","year":"1982","journal-title":"J. Biol. Chem."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1126\/SCIENCE.3131876","article-title":"Interleukin-2: Inception, impact, and implications","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"key":"B179","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1084\/JEM.192.5.755","article-title":"Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma","volume":"192","author":"Smyth","year":"2000","journal-title":"J. Exp. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1073\/PNAS.91.12.5592","article-title":"Granulocyte\/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology","volume":"91","author":"Stanley","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B181","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1172\/JCI115902","article-title":"Widespread long-term gene transfer to mouse skeletal muscles and heart","volume":"90","author":"Stratford-Perricaudet","year":"1992","journal-title":"J. Clin. Investig."},{"key":"B182","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/J.COPBIO.2009.10.012","article-title":"Discovery and development of biopharmaceuticals: Current issues","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/J.COPBIO.2009.10.011","article-title":"Optimization of Fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4049\/JIMMUNOL.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J. Immunol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J. Clin. Investigation"},{"key":"B186","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"B187","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B188","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/J.SMIM.2016.03.003","article-title":"Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies","volume":"28","author":"Taylor","year":"2016","journal-title":"Semin. Immunol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/309418A0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/ijc.24439","article-title":"Cancer incidence and risk factors after solid organ transplantation","volume":"125","author":"Vajdic","year":"2009","journal-title":"Int. J. Cancer"},{"key":"B193","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1182\/blood.v90.11.4485.4485_4485_4492","article-title":"Fc\u03b1RI (CD89) as a novel trigger molecule for bispecific antibody therapy","volume":"90","author":"Valerius","year":"1997","journal-title":"Blood"},{"key":"B194","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/J.JHEP.2010.04.023","article-title":"Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy","volume":"53","author":"Van Der Bij","year":"2010","journal-title":"J. Hepatol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/SJ.LEU.2402424","article-title":"Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils","volume":"16","author":"van der Kolk","year":"2002","journal-title":"Leukemia"},{"key":"B196","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.190.3.355","article-title":"Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation","volume":"190","author":"van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1084\/JEM20210FTA","article-title":"How heidelberger and avery sweetened immunology","volume":"202","author":"Van Epps","year":"2005","journal-title":"J. Exp. Med."},{"key":"B198","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/J.CCELL.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Vargas","year":"2018","journal-title":"Cancer Cell."},{"key":"B199","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/JLB.55.6.816","article-title":"Role of Fc gamma receptors in cancer and infectious disease","volume":"55","author":"Wallace","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.4049\/jimmunol.160.8.3855","article-title":"CTLA-4 regulates tolerance induction and T cell differentiation in vivo","volume":"160","author":"Walunas","year":"1998","journal-title":"J. Immunol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/J.MOLCEL.2016.05.016","article-title":"Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen","volume":"63","author":"Wang","year":"2016","journal-title":"Mol. Cell."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1395111","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"B204","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/NM.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"B205","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/FIMMU.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell."},{"key":"B209","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1128\/JVI.78.8.3897-3905.2004\/ASSET\/AF57C77A-6685-4943-BEC9-F129244166DA\/ASSETS\/GRAPHIC\/ZJV0080418530004.JPEG","article-title":"Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis","volume":"78","author":"Wu","year":"2004","journal-title":"J. Virol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease","volume":"100","author":"Wu","year":"1997","journal-title":"J. Clin. Investig."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3389\/fonc.2021.655630","article-title":"The role and clinical implications of the retinoblastoma (RB)-E2F pathway in gastric cancer","volume":"11","author":"Wu","year":"2021","journal-title":"Front. Oncol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.COPBIO.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/MT.2013.240","article-title":"T-Cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol. Ther."},{"key":"B215","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4161\/MABS.1.4.8895","volume":"1","author":"Zhang","year":"2009","journal-title":"Ofatumumab."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fmicb.2021.707290","article-title":"Oncolytic adenovirus: Prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2023.1140977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T01:47:59Z","timestamp":1676598479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2023.1140977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":216,"alternative-id":["10.3389\/fmmed.2023.1140977"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2023.1140977","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"article-number":"1140977"}}